Jaguar Health, the US-based biopharmaceutical company, has confirmed that its UK subsidiary has provided crofelemer to an infant patient in the European Union diagnosed with microvillus inclusion disease (MVID), a rare and life-threatening genetic disorder that causes severe, persistent diarrhoea and malabsorption.
The drug, derived from the red sap of the Croton lechleri tree, is already approved in the United States for treating diarrhoea in HIV patients on antiretroviral therapy. It has not yet received marketing authorisation from the European Medicines Agency (EMA), but Jaguar is pursuing early-access or compassionate-use provisions to make it available for children with conditions lacking approved treatments.
MVID typically presents in infancy and can lead to profound dehydration, metabolic acidosis, and dependence on parenteral nutrition. Current management is largely supportive, with no specific drug therapy approved in Europe. Jaguar said the supply marks a step towards addressing an unmet medical need in the paediatric rare-disease space.
For UK investors, the development highlights Jaguar's broader strategy to expand crofelemer's regulatory footprint beyond HIV indications into orphan paediatric diseases. The company's shares trade on the Nasdaq, but its UK subsidiary's involvement underscores a growing trend of US biotechs using British bases for European clinical and access operations.
Analysts note that successful early-access cases can bolster the case for formal EMA approval, though the path remains uncertain. The company has not disclosed the specific EU member state involved or the infant's current condition, citing patient confidentiality.
For UK pension and investment portfolios with exposure to biotechnology funds, the story reinforces the high-risk, high-reward nature of orphan drug development. Any future EMA approval for crofelemer in MVID could open a small but valuable market, but near-term revenues from such programmes are likely to be minimal.